RESUMEN
PURPOSE: Large-panel genomic tumor testing (GTT) is an emerging technology with great promise but uncertain clinical value. Previous research has documented variability in academic oncologists' perceptions and use of GTT, but little is known about community oncologists' perceptions of GTT and how perceptions relate to clinicians' intentions to use GTT. METHODS: Community oncology physicians (N = 58) participating in a statewide initiative aimed at improving access to large-panel GTT completed surveys assessing their confidence in using GTT, attitudes regarding the value of GTT, perceptions of barriers to GTT implementation, and future intentions to use GTTs. Descriptive and multivariable regression analyses were conducted to characterize these perceptions and to explore the relationships between them. RESULTS: There was substantial variability in clinicians' perceptions of GTT. Clinicians generally had moderate confidence in their ability to use GTT, but lower confidence in patients' ability to understand test results and access targeted treatment. Clinicians had positive attitudes regarding the value of GTT. Clinicians' future intentions to use GTT were associated with greater confidence in using GTT and greater perceived barriers to implementing GTT, but not with attitudes about the value of GTT. CONCLUSIONS: Community oncologists' perceptions of large-panel genomic tumor testing are variable, and their future intentions to use GTT are associated with both their confidence in and perceived barriers to its use, but not with their attitudes towards GTT. More research is needed to understand other factors that determine how oncologists perceive and use GTT in clinical practice.
Asunto(s)
Actitud del Personal de Salud , Pruebas Genéticas/estadística & datos numéricos , Neoplasias/genética , Oncólogos/psicología , Comprensión , Femenino , Predicción , Encuestas de Atención de la Salud/estadística & datos numéricos , Hematología/estadística & datos numéricos , Humanos , Intención , Maine , Masculino , Análisis de Regresión , Servicios de Salud Rural , Autoimagen , IncertidumbreRESUMEN
Aim: To report the results of a patient epidemiology model for multiple myeloma (MM) treatment by line of therapy (LOT) in the USA. Materials & methods: Surveillance, Epidemiology and End Results registry data and physician surveys were combined to project the incidence, prevalence and the number of MM patients treated with systemic therapy by LOT between 2020 and 2025. Results: Projected complete MM prevalence in the USA in 2020 was 144,922, increasing to 162,339 in 2025. Corresponding unique MM patients by LOT in 2020 were: 53,176 (1st; minimum-maximum: 47,304-59,212), 19,407 (2nd; 15,935-23,273), 6,481 (3rd; 5143-8877), 1649 (4th; 1146-2667) and 426 (5th; 217-876). Conclusion: MM incidence and prevalence by LOT is projected to continue to increase in the USA between 2020 and 2025.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Trasplante de Células Madre Hematopoyéticas/estadística & datos numéricos , Mieloma Múltiple/epidemiología , Pautas de la Práctica en Medicina/estadística & datos numéricos , Anciano , Femenino , Hematología/estadística & datos numéricos , Humanos , Incidencia , Masculino , Oncología Médica/estadística & datos numéricos , Persona de Mediana Edad , Mieloma Múltiple/diagnóstico , Mieloma Múltiple/terapia , Prevalencia , Supervivencia sin Progresión , Estudios Retrospectivos , Programa de VERF/estadística & datos numéricos , Índice de Severidad de la Enfermedad , Estados Unidos/epidemiologíaRESUMEN
BACKGROUND: The histopathological diagnosis of MF is challenging, and there is significant overlap with benign inflammatory processes. Clinical features may be relevant in the assessment of skin biopsies. METHODS: We provided photomicrographs to board-certified dermatopathologists and one hematopathologist with and without accompanying clinical photographs and assessed accuracy and confidence in diagnosing MF. RESULTS: We found that access to clinical photographs improved diagnostic accuracy in both MF and non-MF (distractors); the degree of improvement was significantly higher in the non-MF/distractor category. Across all categories, diagnostic confidence level was higher when clinical images were available. CONCLUSION: These findings suggest that clinical images are useful in making an accurate diagnosis of MF, and may be particularly helpful in ruling it out when an inflammatory disorder is clinically suspected.
Asunto(s)
Inflamación/patología , Micosis Fungoide/diagnóstico , Fotomicrografía/métodos , Neoplasias Cutáneas/patología , Adulto , Biopsia/métodos , Dermatólogos/psicología , Diagnóstico Diferencial , Hematología/estadística & datos numéricos , Humanos , Persona de Mediana Edad , Micosis Fungoide/patología , Micosis Fungoide/ultraestructura , Variaciones Dependientes del Observador , Patólogos/psicología , Competencia Profesional/estadística & datos numéricos , Reproducibilidad de los Resultados , Autoimagen , Piel/patologíaRESUMEN
BACKGROUND: Ensuring that patients with hematologic malignancies have an accurate understanding of their likelihood of cure is important for informed decision making. In a multicenter, longitudinal study, the authors examined discordance in patients' perception of their chance of cure versus that of their hematologists, whether patient-hematologist discordance changed after a consultation with a hematologist, and factors associated with persistent discordance. METHODS: Before and after consultation with a hematologist, patients were asked about their perceived chance of cure (options were <10%, 10%-19%, and up to 90%-100% in 10% increments, and "do not wish to answer"). Hematologists were asked the same question after consultation. Discordance was defined as a difference in response by 2 levels. The McNemar test was used to compare changes in patient-hematologist prognostic discordance from before to after consultation. A generalized linear mixed model was used to examine associations between factors and postconsultation discordance, adjusting for clustering at the hematologist level. RESULTS: A total of 209 patients and 46 hematologists from 4 sites were included in the current study. Before consultation, approximately 61% of dyads were discordant, which improved to 50% after consultation (P < .01). On multivariate analysis, lower educational level (Asunto(s)
Consenso
, Neoplasias Hematológicas/terapia
, Hematología/estadística & datos numéricos
, Adaptación Psicológica
, Toma de Decisiones Clínicas
, Negación en Psicología
, Escolaridad
, Femenino
, Neoplasias Hematológicas/psicología
, Humanos
, Estudios Longitudinales
, Masculino
, Persona de Mediana Edad
, Análisis Multivariante
, Oportunidad Relativa
, Calidad de Vida
, Apoyo Social
, Factores Socioeconómicos
, Encuestas y Cuestionarios/estadística & datos numéricos
, Resultado del Tratamiento
RESUMEN
This study examined the impact of Syrian refugees on 1 area of the Canadian health care sector. We predicted that pediatric hematology clinics across Canada would see a spike in their Syrian refugee patient population in proportion to their recent migration and, as a result, an increase in perceived workload. Data on the number of refugee patients, types of diseases, and perceived workload were gathered from hematology clinics across Canada using a clinical survey (Supplemental Digital Content 1, http://links.lww.com/JPHO/A315). The results showed that Ontario had the most Syrian refugee patients, followed by the Quebec, Western Canadian, and Atlantic regions. The results also showed that perceived workload ranged from "no increase" (4 programs) to "minimal increase" <25% (1 program), "moderate increase" 25% to 75% (4 programs), and "significant increase" >75% (3 programs, 2 of which had no transfusion-dependent thalassemia patients before the immigration).
Asunto(s)
Atención a la Salud/estadística & datos numéricos , Hematología/estadística & datos numéricos , Oncología Médica/estadística & datos numéricos , Neoplasias/terapia , Refugiados/estadística & datos numéricos , Carga de Trabajo , Canadá/epidemiología , Niño , Accesibilidad a los Servicios de Salud , Humanos , Neoplasias/epidemiología , SiriaRESUMEN
PURPOSE: Effective, timely and evidence-based nutritional management is important in patients receiving autologous haematopoietic stem cell transplant (HSCT) to prevent the negative consequences of developing malnutrition. This study describes a robust process for development and implementation of an evidence-based nutrition care pathway for HSCT patients in a tertiary cancer centre. METHODS: A comprehensive review of the literature was completed to identify relevant articles and evidence-based guidelines to inform the development of the pathway. Evidence from the literature review was assessed and utilised to underpin the development of pathway. The pathway was implemented in the haematology service in collaboration with the multidisciplinary haematology team. Dietetic resource requirements for implementation of the pathway were determined and clinician compliance with the care pathway was assessed to evaluate the feasibility of the pathway in supporting delivery of evidence-based care. RESULTS: The evidence-based care pathway was implemented in 2011 with the final care pathway based on recommendations from five international evidence-based guidelines. Overall clinician compliance with delivering nutrition management described in the care pathway was high at 84%. The dietetic resource requirement for implementation of the care pathway was 300 to 400 h per 100 patients depending on conditioning chemotherapy regimen. CONCLUSION: A robust process for developing and implementing a nutrition care pathway for HSCT patients was effective in supporting the delivery of evidence-based nutritional management for patients treated with HSCT.
Asunto(s)
Trasplante de Células Madre Hematopoyéticas , Desnutrición/prevención & control , Terapia Nutricional/métodos , Vías Clínicas/organización & administración , Medicina Basada en la Evidencia , Utilización de Instalaciones y Servicios , Hematología/organización & administración , Hematología/estadística & datos numéricos , Departamentos de Hospitales/organización & administración , Departamentos de Hospitales/estadística & datos numéricos , Humanos , Necesidades Nutricionales , Estado Nutricional , Apoyo Nutricional/métodos , Cooperación del Paciente , Trasplante AutólogoRESUMEN
BACKGROUND: Anticoagulation control in patients with atrial fibrillation (AF) has a multidisciplinary approach although is usually managed by general practitioners (GP) or haematologists. The aim of our study was to assess the quality of anticoagulation control with vitamin K antagonists (VKAs) in relation to the responsible specialist in a "real-world" AF population. METHODS: We consecutively enrolled VKA anticoagulated patients included in the FANTASIIA Registry from 2013 to 2015. We analysed demographical, clinical characteristics and the quality of anticoagulation control according to the specialist responsible (ie GPs or haematologists). RESULTS: Data on 1584 patients were included (42.5% females, mean age 74.0 ± 9.4 years): 977 (61.7%) patients were controlled by GPs and 607 (38.3%) by haematologists. Patients managed by GPs had higher previous heart disease (53.2% vs 43.3%, P < .001), heart failure (32.9% vs 26.5%, P < .008) and dilated cardiomyopathy (15.2% vs 8.7%, P < .001) with better renal function (69.3 ± 24.7 vs 63.1 ± 21.4 mL/min, P < .001) compared to patients managed by haematologists. There was no difference between groups in the type of AF, CHA2 DS2 -VASc or HAS-BLED scores, but patients with electrical cardioversion were more prevalent in GP group. The overall mean time in therapeutic range (TTR) assessed by Rosendaal method was 61.5 ± 24.9%; 52.6% of patients had TTR<65% and 60% of patients had TTR<70%. TTR was significantly lower in patients controlled by haematologists than by GPs (63 ± 24.4 vs 59.2 ± 25.6, P < .005). CONCLUSIONS: About 60% of AF patients anticoagulated with VKAs had poor anticoagulation control (ie TTR<70%), and their management was only slightly better than when it is managed by general practitioners.
Asunto(s)
Anticoagulantes/uso terapéutico , Fibrilación Atrial/tratamiento farmacológico , Calidad de la Atención de Salud/normas , Vitamina K/antagonistas & inhibidores , Anciano , Cardiomiopatía Dilatada/complicaciones , Cardioversión Eléctrica/estadística & datos numéricos , Femenino , Medicina General/normas , Medicina General/estadística & datos numéricos , Insuficiencia Cardíaca/complicaciones , Hematología/normas , Hematología/estadística & datos numéricos , Humanos , Riñón/fisiología , Masculino , Estudios Prospectivos , Calidad de la Atención de Salud/estadística & datos numéricos , Sistema de Registros , Factores de RiesgoRESUMEN
Hematologists and oncologists in private practice play a central role in the care provided for cancer patients. The present study analyzes stress and relaxation aspects in the work of hematologists and oncologists in private practice in Germany in relation to emotional exhaustion, as a core dimension of burnout syndrome. The study focuses on the opportunities for internal recovery using breaks and time out during the working day, the frequency of working on weekends and on vacation, and the physician's work-home and home-work conflict. Postulated associations between the constructs were analyzed using a structural equation model. If work leads to conflicts in private life (work-home conflict), it is associated with greater emotional exhaustion. Working frequently at the weekend is associated with greater work-home conflict and indirectly with greater emotional exhaustion. By contrast, the availability of opportunities to relax and recover during the working day is associated with less work-home conflict and indirectly with less emotional exhaustion. These results underline the importance of internal recovery opportunities during the working day and a successful interplay between working and private life for the health of outpatient hematologists and oncologists.
Asunto(s)
Agotamiento Profesional/epidemiología , Desgaste por Empatía/epidemiología , Hematología/estadística & datos numéricos , Oncología Médica/estadística & datos numéricos , Médicos/estadística & datos numéricos , Práctica Privada/estadística & datos numéricos , Equilibrio entre Vida Personal y Laboral/estadística & datos numéricos , Adulto , Femenino , Alemania/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Oncólogos/estadística & datos numéricosAsunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Hematología/estadística & datos numéricos , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicaciones , Leucemia-Linfoma Linfoblástico de Células Precursoras/mortalidad , Adolescente , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/economía , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Bases de Datos Factuales , Progresión de la Enfermedad , Estudios de Seguimiento , Hematología/normas , Humanos , India/epidemiología , Infecciones/epidemiología , Infecciones/mortalidad , Cumplimiento de la Medicación/psicología , Cumplimiento de la Medicación/estadística & datos numéricos , Neoplasia Residual/epidemiología , Evaluación de Resultado en la Atención de Salud , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/epidemiología , Estudios Retrospectivos , Factores Socioeconómicos , Análisis de Supervivencia , Adulto JovenAsunto(s)
COVID-19/epidemiología , Neoplasias Hematológicas/complicaciones , Sistema de Registros/estadística & datos numéricos , SARS-CoV-2/inmunología , Adulto , Factores de Edad , Anciano , Antivirales/uso terapéutico , COVID-19/diagnóstico , COVID-19/inmunología , COVID-19/virología , Prueba de COVID-19/estadística & datos numéricos , Femenino , Neoplasias Hematológicas/inmunología , Neoplasias Hematológicas/terapia , Hematología/estadística & datos numéricos , Hospitalización/estadística & datos numéricos , Humanos , Unidades de Cuidados Intensivos/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Mortalidad , Prevalencia , Medición de Riesgo/métodos , Medición de Riesgo/estadística & datos numéricos , Factores de Riesgo , SARS-CoV-2/aislamiento & purificación , Índice de Severidad de la Enfermedad , Sociedades Científicas/estadística & datos numéricos , Análisis de Supervivencia , Estados Unidos/epidemiología , Adulto Joven , Tratamiento Farmacológico de COVID-19RESUMEN
Various treatment options exist for patients with chronic lymphocytic leukaemia (CLL). Clinical registries provide insight into routine treatment and identify changes in treatment over time. The Tumour Registry Lymphatic Neoplasms prospectively collects data on the treatment of patients with lymphoid B-cell neoplasm as administered by office-based haematologists in Germany. Data on patient and tumour characteristics, co-morbidities, systemic treatments, and outcome parameters are recorded. Eight hundred and six patients with CLL were recruited between May 2009 and August 2013. At the start of first-line treatment, median age was 71 years, 64% were male, and 44% had a Binet stage C disease. The most frequently used first-line/second-line regimens were bendamustine + rituximab (BR, 56%/55%), fludarabine + cyclophosphamide + rituximab (FCR, 22%/11%), and bendamustine (B, 5%/9%). Chlorambucil was used in only 7% (first-line) and 6% (second-line) of patients. Patients treated with FCR were younger and healthier than patients treated with BR. Overall, 91% of first-line treatments were successful (40% complete response). Real-life patient populations differ considerably from patients treated in randomized controlled trials. BR and FCR dominate the first-line and second-line treatments of CLL by office-based haematologists in Germany. Future analysis will investigate progression-free and overall survival times.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Leucemia Linfocítica Crónica de Células B/tratamiento farmacológico , Sistema de Registros/estadística & datos numéricos , Anticuerpos Monoclonales de Origen Murino/administración & dosificación , Clorhidrato de Bendamustina , Clorambucilo/administración & dosificación , Ciclofosfamida/administración & dosificación , Femenino , Alemania , Hematología/métodos , Hematología/estadística & datos numéricos , Humanos , Masculino , Compuestos de Mostaza Nitrogenada/administración & dosificación , Visita a Consultorio Médico/estadística & datos numéricos , Prednisona/administración & dosificación , Estudios Prospectivos , Rituximab , Vidarabina/administración & dosificación , Vidarabina/análogos & derivadosRESUMEN
PURPOSE: Peripherally inserted central venous catheters (PICC) have been successfully used to provide central access for chemotherapy and frequent transfusions. The purpose of this study was to assess the feasibility of PICCs and determine PICC-related complications in pediatric hematology/oncology patients in a resource-poor setting. METHODS: All pediatric patients (age below 16 y) with hematologic and malignant disorders who underwent PICC line insertion at Aga Khan University Hospital from January 2008 to June 2010 were enrolled in the study. Demographic features, primary diagnosis, catheter days, complications, and reasons for removal of device were recorded. RESULTS: Total of 36 PICC lines were inserted in 32 pediatric patients. Complication rate of 5.29/1000 catheter days was recorded. Our study showed comparable complication profile such as infection rate, occlusion, breakage, and dislodgement. The median catheter life was found to be 69 days. CONCLUSIONS: We conclude that PICC lines are feasible in a resource-poor setting and recommend its use for chemotherapy administration and prolonged venous access.
Asunto(s)
Cateterismo Venoso Central/efectos adversos , Cateterismo Venoso Central/estadística & datos numéricos , Catéteres Venosos Centrales/efectos adversos , Adolescente , Infecciones Relacionadas con Catéteres/epidemiología , Niño , Preescolar , Países en Desarrollo , Femenino , Enfermedades Hematológicas/tratamiento farmacológico , Hematología/métodos , Hematología/estadística & datos numéricos , Humanos , Lactante , Recién Nacido , Masculino , Oncología Médica/métodos , Oncología Médica/estadística & datos numéricos , Neoplasias/tratamiento farmacológico , Pakistán , Atención Terciaria de Salud/estadística & datos numéricosRESUMEN
BACKGROUND: Invasive aspergillosis (IA) is associated with a high mortality rate despite the introduction of new antifungal agents. Several therapeutic strategies have been proposed to improve mortality rates in IA, including combination of drugs. METHODS: Here, we report the outcome of treatments based on a combination of antifungal agents on IA, including voriconazole and liposomal amphotericin B, in a pediatric population from 2001 to 2010. Our population included children with diverse hematological diseases or with bone marrow transplantation. RESULTS: Over a 10-year period, we diagnosed 19 cases (2,8%) of invasive pulmonary aspergillosis with an overall survival rate of 58%. CONCLUSION: Compared with the previous study conducted from 1986 to 2000, the overall survival rate (bone marrow transplantation excluded) greatly improved (12.5% to 58%), especially for patients treated for acute leukemia.
Asunto(s)
Antifúngicos/uso terapéutico , Aspergilosis Pulmonar Invasiva/tratamiento farmacológico , Aspergilosis Pulmonar Invasiva/mortalidad , Adolescente , Antineoplásicos/efectos adversos , Niño , Preescolar , Femenino , Hematología/estadística & datos numéricos , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Humanos , Huésped Inmunocomprometido , Lactante , Aspergilosis Pulmonar Invasiva/inmunología , Leucemia/complicaciones , Leucemia/tratamiento farmacológico , Masculino , Pediatría/estadística & datos numéricos , Estudios RetrospectivosRESUMEN
BACKGROUND: Increased risk for infertility from cancer treatment and fear of health impairment in their offspring may prevent survivors of childhood cancer from having own children. Even though most studies report no increased risk for malformations, in our German fertility study 2008 a higher occurrence of cleft lip and palate was found in offspring of former patients. METHODS: Since 2010 we assess offspring's health in a survey-based multicenter study, comparing diseases, well-being, healthcare utilization and health-related behavior between offspring from survivors, siblings or the general population. Within a first nationwide survey wave survivors who were known to have at least one child by previous fertility studies, received a questionnaire supported by the German Childhood Cancer Registry. Questionnaires were based on the KiGGS study on children's health in the German general population conducted by the Robert-Koch Institute (n=17,641). RESULTS: Questionnaires on 418 children were answered by 65% (254/393) of survivors contacted to participate in the first nationwide offspring study wave. Participants were more likely to be female (p<0.01), to have achieved higher educational levels (p<0.05) and to be a survivor of a soft tissue tumor (p<0.05). Former patients expressed moderate to high anxiety for the occurrence of cancer in 74% and feared other diseases in their children in 20%. CONCLUSION: Offspring health is a topic of major relevance to former patients. Our offspring study is currently being extended to ~1500 offspring of childhood cancer survivors in Europe.
Asunto(s)
Ensayos Clínicos como Asunto/estadística & datos numéricos , Hematología/estadística & datos numéricos , Hematología/tendencias , Oncología Médica/estadística & datos numéricos , Oncología Médica/tendencias , Pediatría/estadística & datos numéricos , Pediatría/tendencias , Publicaciones/estadística & datos numéricos , Publicaciones/tendencias , Adolescente , Niño , Preescolar , Protocolos Clínicos , Estudios de Cohortes , Predicción , Alemania , Humanos , Lactante , Cooperación Internacional , Lenguaje , Estudios Retrospectivos , Sociedades Médicas/estadística & datos numéricos , Sociedades Médicas/tendenciasRESUMEN
BACKGROUND: There is scope to further improve the safety of transfusion practice within the United Kingdom. This study aims to identify the current role of junior doctors in the transfusion process and to assess their competency to appropriately prescribe blood and blood products to patients. STUDY DESIGN AND METHODS: Transfusion competency in junior doctors training in a single region was addressed through anonymized questionnaires assessing factual knowledge, personal reflection, and documented evidence of competency. Factual knowledge comprised 33 true-false questions (competency score) covering indications for transfusion, special requirements, risks of transfusion, and guidelines for testing in transfusion. Background data on current practice and education in transfusion medicine were addressed using multiple-choice and single-response questions. RESULTS: A total of 787 newly qualified doctors, comprising 79% of first-year (F1) and 62% of second-year (F2) Foundation doctors, completed the assessment over a 3-week period. There was no improvement in competency score between F1 and F2 doctors (p = 0.1). Competency scores correlated most strongly with undergraduate education in transfusion medicine and attendance at hospital induction (p < 0.01). Junior doctors had a high confidence level with regard to prescribing blood, although only 78% were aware they had been competency assessed against national standards. CONCLUSION: Junior doctors are involved in sampling, prescribing, consenting, and documenting transfusion practice frequently enough to maintain competency. They are rarely involved in the collection, bedside checking, or administration of blood despite current curriculum requirements. There is scope to significantly improve both the training and the assessment of transfusion competency in doctors.
Asunto(s)
Transfusión Sanguínea/normas , Competencia Clínica , Cuerpo Médico de Hospitales , Medicina Transfusional/educación , Transfusión Sanguínea/estadística & datos numéricos , Adhesión a Directriz/estadística & datos numéricos , Hematología/educación , Hematología/normas , Hematología/estadística & datos numéricos , Humanos , Conocimiento , Errores Médicos/estadística & datos numéricos , Cuerpo Médico de Hospitales/normas , Cuerpo Médico de Hospitales/estadística & datos numéricos , Medicina/estadística & datos numéricos , Práctica Profesional/normas , Práctica Profesional/estadística & datos numéricos , Estudios Retrospectivos , Medicina Transfusional/normasRESUMEN
Hematology referral for evaluation is a key step for hematopoietic stem cell transplantation for sickle cell disease (SCD). Pediatric SCD providers in the US Northeast (New York-Mid-Atlantic and New England regions) were surveyed anonymously for perspectives and practices regarding transplant referral and compared by whether they practiced at SCD transplant centers. Data were analyzed using the Fisher exact test, χ test, and logistic regression. Half of the respondents practiced primarily at transplant sites. Most (79%) were enthusiastic about transplant for SCD and 78% had recently referred ≥1 child for evaluation. Overall, 77% limited referral to certain sickle hemoglobinopathies and 44% preferred referral for ß-thalassemia to SCD. Indications selected for referral resembled current transplant criteria, plus family request or poor response to therapy. Referral for children on chronic transfusions predicted enthusiasm and prior referral. Many (66%) referred children with multiple SCD complications, even without matched sibling donors, 37% with sibling donors despite limited disease. Practitioners at transplant centers more commonly accepted event-free survival rates of ≤90% (P=0.002). Northeastern providers expressed varying enthusiasm for referral for evaluation based on eligibility, donor availability, and acceptable risk, with modestly more interest from practitioners at transplant centers. Differing provider perspectives may affect patient referral for transplant consideration.
Asunto(s)
Anemia de Células Falciformes/terapia , Hematología/estadística & datos numéricos , Trasplante de Células Madre Hematopoyéticas , Pediatría/estadística & datos numéricos , Práctica Profesional/estadística & datos numéricos , Derivación y Consulta/estadística & datos numéricos , Adulto , Transfusión Sanguínea , Niño , Preescolar , Estudios Transversales , Supervivencia sin Enfermedad , Femenino , Encuestas de Atención de la Salud , Humanos , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Tamizaje Neonatal , New England , Adulto Joven , Talasemia beta/terapiaRESUMEN
BACKGROUND: Our purpose was to identify physicians' individual characteristics, attitudes, and organizational contextual factors associated with higher enrollment of patients in cancer clinical trials among physician participants in the National Cancer Institute's Community Clinical Oncology Program (CCOP). We hypothesized that physicians' individual characteristics, such as age, medical specialty, tenure, CCOP organizational factors (i.e. policies and procedures to encourage enrollment), and attitudes toward participating in CCOP would directly determine enrollment. We also hypothesized that physicians' characteristics and CCOP organizational factors would influence physicians' attitudes toward participating in CCOP, which in turn would predict enrollment. METHODS: We evaluated enrollment in National Cancer Institute-sponsored cancer clinical trials in 2011 among 481 physician participants using Structural Equation Modeling. The data sources include CCOP Annual Progress Reports, two surveys of CCOP administrators and physician participants, and the American Medical Association Masterfile. RESULTS: Physicians with more positive attitudes toward participating in CCOP enrolled more patients than physicians with less positive attitudes. In addition, physicians who practiced in CCOPs that had more supportive policies and practices in place to encourage enrollment (i.e. offered trainings, provided support to screen and enroll patients, gave incentives to enroll patients, instituted minimum accrual expectations) also significantly enrolled more patients. Physician status as CCOP Principal Investigator had a positive direct effect on enrollment, while physician age and non-oncology medical specialty had negative direct effects on enrollment. Neither physicians' characteristics nor CCOP organizational factors indirectly influenced enrollment through an effect on physician attitudes. CONCLUSION: We examined whether individual physicians' characteristics and attitudes, as well as CCOP organizational factors, influenced patient enrollment in cancer clinical trials among CCOP physicians. Physician attitudes and CCOP organizational factors had positive direct effects, but not indirect effects, on physician enrollment of patients. Our results could be used to develop physician-directed strategies aimed at increasing involvement in clinical research. For example, administrators may want to ensure physicians have access to support staff to help screen and enroll patients or institute minimum accrual expectations. Our results also highlight the importance of recruiting physicians for volunteer clinical research programs whose attitudes and values align with programmatic goals. Given that physician involvement is a key determinant of patient enrollment in clinical trials, these interventions could expand the overall number of patients involved in cancer research. These strategies will be increasingly important as the CCOP network continues to evolve.
Asunto(s)
Ensayos Clínicos como Asunto , Cirugía General/estadística & datos numéricos , Hematología/estadística & datos numéricos , Oncología Médica/estadística & datos numéricos , Neoplasias/terapia , Selección de Paciente , Médicos/estadística & datos numéricos , Oncología por Radiación/estadística & datos numéricos , Adulto , Factores de Edad , Actitud del Personal de Salud , Femenino , Cirugía General/organización & administración , Hematología/organización & administración , Humanos , Masculino , Oncología Médica/organización & administración , Persona de Mediana Edad , National Cancer Institute (U.S.) , Oncología por Radiación/organización & administración , Estados UnidosRESUMEN
Patients with myeloma are at high risk of venous thromboembolism (VTE). There is no consensus about what agent to use or what haematologists are doing in clinical practice. A survey was sent to haematologists treating patients with myeloma in Ireland. 32/45 (71%) responded. 13/28 (46%) felt that VTE affected < 5% of patients. However, 8/28 (29%) felt it affected 10-19%. Thromboprophylaxis was most commonly used in patients on lenalidomide; 25/28 (89%) and thalidomide; 23/28 (82%). 23/28 (82%) used LMWH and 20/28 (71%) used aspirin either very frequently or frequently. 3/28 (11%) had used dabigatran/rivaroxaban despite there being little evidence to support their use. Efficacy was the most important factor in choosing an agent for 25/28 (89%). Bleeding was not felt to be an issue 15/29 (52%) were not using thromboprophylaxis guidelines. This survey demonstrated wide variation in the beliefs and practices regarding the burden of VTE in patients with myeloma and the need for thromboprophylaxis.
Asunto(s)
Fármacos Hematológicos , Mieloma Múltiple/complicaciones , Pautas de la Práctica en Medicina , Servicios Preventivos de Salud , Tromboembolia Venosa , Actitud del Personal de Salud , Encuestas de Atención de la Salud , Fármacos Hematológicos/clasificación , Fármacos Hematológicos/uso terapéutico , Hematología/métodos , Hematología/estadística & datos numéricos , Humanos , Irlanda , Participación del Paciente , Pautas de la Práctica en Medicina/normas , Pautas de la Práctica en Medicina/estadística & datos numéricos , Servicios Preventivos de Salud/métodos , Servicios Preventivos de Salud/normas , Medición de Riesgo , Resultado del Tratamiento , Tromboembolia Venosa/etiología , Tromboembolia Venosa/prevención & control , Tromboembolia Venosa/psicologíaRESUMEN
BACKGROUND: In 2009, Germany enacted a new law supporting advance directives that led to heated discussions in the media and the public. 3 years after the law passed, we surveyed patients with malignant diseases with regards to their views on advance directives. PATIENTS AND METHODS: Between September 2011 and July 2012 an anonymous survey on advance directives was conducted among 617 patients at the hematology and oncology outpatient department of the University Hospital Mannheim, using a standardized questionnaire developed for this investigation. RESULTS: Of the 503 patients who returned the questionnaire, 31% (n = 157) indicated having an advance directive. Of these 157, 54% (n = 85) completed the advance directive after 2009. 56% (282 out of 503) desired more information on advance directives. Of these, 71% (201 out of 282) wanted their general physician and 45% (128 out of 282) their specialist, to provide more information about this issue. Of the 339 patients without an advance directive, 47% (n = 158) stated that they had 'not worried about that yet'. CONCLUSION: Although the percentage of patients with advance directives has increased since the legislative amendment, more information is still required by patients. It is recommended that physicians should discuss advance directives more frequently with their patients.
Asunto(s)
Directivas Anticipadas/estadística & datos numéricos , Instituciones de Atención Ambulatoria/estadística & datos numéricos , Alfabetización en Salud/estadística & datos numéricos , Hematología/estadística & datos numéricos , Oncología Médica/estadística & datos numéricos , Neoplasias/epidemiología , Participación del Paciente/estadística & datos numéricos , Adolescente , Adulto , Distribución por Edad , Anciano , Anciano de 80 o más Años , Escolaridad , Femenino , Alemania/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Neoplasias/terapia , Prevalencia , Distribución por Sexo , Encuestas y Cuestionarios , Adulto JovenRESUMEN
BACKGROUND: The purpose of this study was to evaluate the effect of legal regulations for clinical trials on study centers participating in investigator-initiated trials (IITs) in the field of hematology/oncology. METHOD: Questionnaires were sent out to the heads of hematology-oncology study centers. RESULTS: Medical units participating in IITs have a good infrastructure and extensive experience in clinical trials. Depending on indication, a high proportion of patients have been treated in studies with the purpose to improve outcome. However, 35% of the responders will reduce their participation in IITs in the future due to a lack of financial support for staff involved in the extensive organizational tasks. CONCLUSIONS: The widely recognized research field in therapy optimization trials in hematology and oncology in Germany is at risk. This will have negative effects on the patients as highly sophisticated protocols will no longer be initiated in several study centers, resulting in the loss of valuable data for the improvement of patient therapy and outcome. To stop this development, legislators as well as regulatory authorities and health insurances need to make the necessary changes in the legal framework.